Three awards from the Cardiovascular and Metabolic Diseases Pathology and Pharmacology Group at the 29th Congress on Atherosclerosis
On December 4–6, 2025, the 29th Congress on Atherosclerosis, organized by the Czech Society for Atherosclerosis, took place in Olomouc. The congress also included an evaluation of the best publications in the field of atherosclerosis for 2024/2025. PharmDr. Jana Urbánková Rathouská, PhD, from the Group of Pathology and Pharmacology of Cardiovascular and Metabolic Diseases at the Faculty of Pharmacy, Charles University, led by Prof. PharmDr. Petr Nachtigal, Ph.D., won third place for the best publication. The publication dealt with the significance of increased concentrations of soluble endoglin in patients with myocardial infarction. Rathouska, J. U., Mrazkova, J., Andrys, C., Jankovicova, K., Tripska, K., Fikrova, P., Nemeckova, I., Eissazadeh, S., Wohlfahrt, P., Pitha, J., and Nachtigal, P. (2025). Soluble endoglin reflects endothelial dysfunction in myocardial infarction patients: a retrospective observational study. Int J Med Sci 22, 3220–3228 [IF= 3.2], AIS 0.689, (Q1).
The congress also featured a moderated poster session, in which 14 posters by authors under the age of 40 competed. First place went to PharmDr. Niloufar Mohammadi with a poster entitled "Targeting Human Endoglin Suppresses Hepatic Inflammation and Fibrosis in Transgenic Mouse Model of MASH." Third place went to PharmDr. Petra Fikrová, PhD, with her poster entitled "Divergent effects of endoglin inhibition on human hepatic stellate cells activation"
We would like to congratulate all the winners and co-authors.
Text and photos: Prof. PharmDr. Petr Nachtigal, Ph.D.